GGrantIndex
← Leaderboards

Schepens Eye Research Institute

Boston, MA

Compare ↔
$343,202,804
Total funding
223
Grants

Funding over time

peak $22.6M · FY2005–25
$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$344,518,717 · 224

By mechanism

R01$272,626,233 · 98
R21$16,255,070 · 32
P30$8,611,885 · 19
R24$7,181,387 · 1
T32$4,269,018 · 1
C06$3,777,093 · 6

Investigators at Schepens Eye Research Institute

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Menglu Yang$896,0461 gr2Nerea Zabaleta$668,5691 gr3Anil K. Chekuri$638,2671 gr

Emerging Leaders

6–10 yrs in

1Yihe Chen$4,458,6155 gr2Daniel Sun$3,021,7502 gr3Mengyu Wang$2,633,7453 gr4Diego Sepulveda-Falla$1,787,4401 gr5Lucy Q Shen$1,443,0221 gr6Jae-Hyun Jung$1,303,1551 gr7Varun Kumar$747,0001 gr8Shrinivas Pundlik$550,3401 gr

All-Time

Most funded here, all years

1Eli Peli$29,741,6067 gr2Reza Dana$26,664,4767 gr3Darlene A Dartt$20,106,3418 gr4Ann Marshak-Rothstein$17,258,77313 gr5Andrius Kazlauskas$15,049,0787 gr6Fu-Shin X Yu$14,544,5584 gr7James D Zieske$12,320,6394 gr8Joan Stein-Streilein$10,989,4576 gr

Largest grants

Charting vascular contributions to white matter disease in familial Alzheimer's disease and CADASIL$3,524,983
RF1 · FY2018 · NS
Bioengineering of Bruch's Membrane for the treatment of Age-related Macular Degen$2,918,000
DP2 · FY2009 · OD
Humanization of a Notch 3 agonist antibody for pre-clinical development of a CADASIL treatment$2,204,584
UF1 · FY2021 · NS
RENOVATION OF RESEARCH BUILDING$2,000,000
C06 · FY2000 · RR
Core Grant for Vision Research$1,799,099
P30 · FY2004 · EY
CONTINUED RENOVATION OF RESEARCH BLDG$1,777,093
C06 · FY2002 · RR
Topical Neurokinin-1 Receptor Antagonist as an Effective Non-addictive Analgesic for Ocular Pain$1,559,917
R61 · FY2024 · NS
Ocular Immune Regulation by Mesenchymal Stem Cells$1,477,500
R01 · FY2025 · EY
ENGINEERING APPROACHES TO LOW VISION REHABILITATION$1,430,525
R24 · FY2002 · EY
ENGINEERING APPROACHES TO LOW VISION REHABILITATION$1,351,333
R01 · FY2007 · EY
ENGINEERING APPROACHES TO LOW VISION REHABILITATION$1,344,583
R01 · FY2006 · EY
Harvard-wide Program on Antibiotic Resistance$1,315,913
P01 · FY2009 · AI
ENGINEERING APPROACHES TO LOW VISION REHABILITATION$1,293,186
R01 · FY2009 · EY
ENGINEERING APPROACHES TO LOW VISION REHABILITATION$1,276,822
R24 · FY2000 · EY
ENGINEERING APPROACHES TO LOW VISION REHABILITATION$1,260,161
R01 · FY2010 · EY
ENGINEERING APPROACHES TO LOW VISION REHABILITATION$1,248,798
R01 · FY2008 · EY
ANTERIOR CHAMBER INFLUENCE ON OCULAR ANTIGENS$1,217,000
R01 · FY2001 · EY
Core Grant for Vision Research$1,192,013
P30 · FY2005 · EY
ENGINEERING APPROACHES TO LOW VISION REHABILITATION$1,148,561
R24 · FY2001 · EY
Anesthetic-Eluting Contact Lens for Corneal Pain$1,120,889
UG3 · FY2023 · NS